Open AccessGlucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes
Author(s) -
Richeek Pradhan,
Hui Yin,
Oriana Hoi Yun Yu,
Laurent Azoulay
Publication year - 2022
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc21-1953
Subject(s) - medicine , nonalcoholic fatty liver disease , hazard ratio , liraglutide , type 2 diabetes , endocrinology , vildagliptin , gastroenterology , dipeptidyl peptidase 4 , diabetes mellitus , dulaglutide , glucagon like peptide 1 , exenatide , lower risk , transaminase , fatty liver , disease , confidence interval , biochemistry , enzyme , chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom